Various clinical presentations of uveitis associated with durvalumab treatment

Radiology and Oncology

Vrankar Martina¹  Janzic Urska²  Fakin Ana³  Mekjavic Polona Jaki³  Vrabic Nika³  Valentincic Natasa Vidovic³ 

[1] Institute of Oncology Ljubljana, Ljubljana, Slovenia;University Clinic of Pulmonary and Allergic Diseases Golnik, Ljubljana, Slovenia;University Eye Clinic, University Clinical Centre Ljubljana, LjubljanaSlovenia;

关键词: durvalumab;    uveitis;    optic disc oedema;    immune checkpoint inhibitor;    adverse effects;   

DOI  :  10.2478/raon-2022-0007

来源: DOAJ

【 摘 要 】

Immune checkpoint inhibitors (ICI) are becoming increasingly common in treating several cancer types. Durvalumab is a human IgG1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80 and has recently been approved for the treatment of extensive-stage small-cell lung cancer (ES-SCLC) and locally advanced unresectable (NSCLC). The present review aimed to analyse immune-mediated uveitis, secondary to durvalumab treatment, through a review of the literature and a presentation of two clinical cases.

【 授权许可】

Unknown